RVMD
Revolution Medicines, Inc. trades as RVMD and has a market capitalization of $30.65 B, making it the #454 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $0.00 and net income of -$1.13B. This page tracks Revolution Medicines, Inc. through 782 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -207.2% to -3765.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| Insider trade | 4 | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-28 |
| Annual report to shareholders | ARS | 2026-04-28 |
| Insider sale notice | 144 | 2026-04-27 |
| Proxy statement | DEF 14A | 2026-04-27 |
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations . Following the live webcast, a replay will be available on the company’s website for at least 14 days.
Revolution Medicines Statement on FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer | Revolution Medicines
The largest companies sharing Revolution Medicines, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Revolution Medicines, Inc. (RVMD) has a market capitalization of $30.65 B as of 2026-06-10, ranking #454 among US-listed companies.
Revolution Medicines, Inc. reported revenue of $0.00 for fiscal year 2025.
In its latest fiscal year Revolution Medicines, Inc. reported a net loss of $1.13B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.